Jan Steyaert | |
---|---|
Nationality | Belgian |
Alma mater | Vrije Universiteit Brussels |
Title | Prof. |
Jan Steyaert is a Belgian bioengineer and molecular biologist. He started his career as an enzymologist but the Steyaertlab is best known for pioneering work on (engineered) nanobodies for applications in structural biology, omics and drug design. He is full professor and teaches biochemistry at the Vrije Universiteit Brussel and Director of the VIB-VUB Center for Structural Biology, one of the Research Centers of the Vlaams Instituut voor Biotechnologie (VIB). He was involved in the foundation of three spin-off companies: Ablynx, Biotalys, and Confo Therapeutics.
Steyaert was born in Ukkel, Belgium. He grew up in the Flemish village of Alsemberg. He obtained a Master in Bioengineering at the Vrije Universiteit Brussel. For his PhD, he moved to Plant Genetic Systems, one of the very first biotech companies in Belgium. After obtaining his Ph.D., he relocated to Kenya to perform postdoctoral research at ILRAD (now ILRI), the International Livestock Research Institute.
In 1995, he returned to Belgium to become assistant professor in the Structural Biology Laboratory of Lode Wyns.
From 2015 to 2017, he was a Francqui Research Professor.
In 2020, he was elected as a member of the European Molecular Biology Organization. [1]
Jan Steyaert pioneered the use of nanobodies as tools in structural biology. Nanobodies are the variable domains of heavy-chain only antibodies that naturally occur in camelids. Because of their small size and their beneficial biochemical and economic properties (size, affinity, specificity, stability, production cost), Steyaert applies nanobodies to freeze dynamic proteins into single functional conformations. X-ray crystallography or cryogenic electron microscopy can then be used to determine the structures of different stills of the same moving biomolecule. [2] [3] [4]
In collaboration with Brian Kobilka the research team of Steyaert generated nanobodies [5] [6] elucidate the crystal structure of several G-protein-coupled receptors (GPCR), including the ß2 adrenergic receptor, [7] [8] [9] the muscarinic acetylcholine receptor, [10] [11] the μ-opioid receptor, [12] [13] the metabotropic glutamate receptors [14] [15] and, as a first, the crystal structure of a GPCR-G protein complex. [16] [17]
Steyaert also applies nanobodies as versatile tools for investigating GPCR dynamics in vitro and inside cells, [18] [19] and for improved drug discovery. [20] [21] [22] [23] More recently, he started engineering Nanobodies for applications in cryo-EM.
In 2016 he received The Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery [24] for his pioneering work in the field of nanobody-enabled structural biology.
From 2019 onwards, Jan Steyaert is a Web of Science Highly Cited Researcher in the field of Biology and Biochemistry.
In 2022 he won the Brandeis’ 24th Jacob and Louise Gabbay Award in Biotechnology and Medicine in recognition of his contributions to structural biology through the development of Camelid single-domain antibodies or nanobodies.
In 2024 he was rewarded an ERC advanced grant form the ERC council.
G protein-coupled receptors (GPCRs), also known as seven-(pass)-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptors, and G protein-linked receptors (GPLR), form a large group of evolutionarily related proteins that are cell surface receptors that detect molecules outside the cell and activate cellular responses. They are coupled with G proteins. They pass through the cell membrane seven times in the form of six loops of amino acid residues, which is why they are sometimes referred to as seven-transmembrane receptors. Ligands can bind either to the extracellular N-terminus and loops or to the binding site within transmembrane helices. They are all activated by agonists, although a spontaneous auto-activation of an empty receptor has also been observed.
An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the agonist, while an inverse agonist causes an action opposite to that of the agonist.
Inositol trisphosphate receptor (InsP3R) is a membrane glycoprotein complex acting as a Ca2+ channel activated by inositol trisphosphate (InsP3). InsP3R is very diverse among organisms, and is necessary for the control of cellular and physiological processes including cell division, cell proliferation, apoptosis, fertilization, development, behavior, learning and memory. Inositol triphosphate receptor represents a dominant second messenger leading to the release of Ca2+ from intracellular store sites. There is strong evidence suggesting that the InsP3R plays an important role in the conversion of external stimuli to intracellular Ca2+ signals characterized by complex patterns relative to both space and time, such as Ca2+ waves and oscillations.
Functional selectivity is the ligand-dependent selectivity for certain signal transduction pathways relative to a reference ligand at the same receptor. Functional selectivity can be present when a receptor has several possible signal transduction pathways. To which degree each pathway is activated thus depends on which ligand binds to the receptor. Functional selectivity, or biased signaling, is most extensively characterized at G protein coupled receptors (GPCRs). A number of biased agonists, such as those at muscarinic M2 receptors tested as analgesics or antiproliferative drugs, or those at opioid receptors that mediate pain, show potential at various receptor families to increase beneficial properties while reducing side effects. For example, pre-clinical studies with G protein biased agonists at the μ-opioid receptor show equivalent efficacy for treating pain with reduced risk for addictive potential and respiratory depression. Studies within the chemokine receptor system also suggest that GPCR biased agonism is physiologically relevant. For example, a beta-arrestin biased agonist of the chemokine receptor CXCR3 induced greater chemotaxis of T cells relative to a G protein biased agonist.
A single-domain antibody (sdAb), also known as a Nanobody, is an antibody fragment consisting of a single monomeric variable antibody domain. Like a whole antibody, it is able to bind selectively to a specific antigen. With a molecular weight of only 12–15 kDa, single-domain antibodies are much smaller than common antibodies which are composed of two heavy protein chains and two light chains, and even smaller than Fab fragments and single-chain variable fragments.
The beta-2 adrenergic receptor, also known as ADRB2, is a cell membrane-spanning beta-adrenergic receptor that binds epinephrine (adrenaline), a hormone and neurotransmitter whose signaling, via adenylate cyclase stimulation through trimeric Gs proteins, increases cAMP, and, via downstream L-type calcium channel interaction, mediates physiologic responses such as smooth muscle relaxation and bronchodilation.
Heterotrimeric G protein, also sometimes referred to as the "large" G proteins are membrane-associated G proteins that form a heterotrimeric complex. The biggest non-structural difference between heterotrimeric and monomeric G protein is that heterotrimeric proteins bind to their cell-surface receptors, called G protein-coupled receptors (GPCR), directly. These G proteins are made up of alpha (α), beta (β) and gamma (γ) subunits. The alpha subunit is attached to either a GTP or GDP, which serves as an on-off switch for the activation of G-protein.
The μ-opioid receptors (MOR) are a class of opioid receptors with a high affinity for enkephalins and beta-endorphin, but a low affinity for dynorphins. They are also referred to as μ(mu)-opioid peptide (MOP) receptors. The prototypical μ-opioid receptor agonist is morphine, the primary psychoactive alkaloid in opium and for which the receptor was named, with mu being the first letter of Morpheus, the compound's namesake in the original Greek. It is an inhibitory G-protein coupled receptor that activates the Gi alpha subunit, inhibiting adenylate cyclase activity, lowering cAMP levels.
Naltrindole is a highly potent, highly selective delta opioid receptor antagonist used in biomedical research. In May 2012 a paper was published in Nature with the structure of naltrindole in complex with the mouse δ-opioid G-protein coupled receptor, solved by X-ray crystallography.
GPR156, is a human gene which encodes a G protein-coupled receptor belonging to metabotropic glutamate receptor subfamily. By sequence homology, this gene was proposed as being a possible GABAB receptor subunit, however when expressed in cells alone or with other GABAB subunits, no response to GABAB ligands could be detected. In vitro studies on GPR156 constitutive activity revealed a high level of basal activation and coupling with members of the Gi/Go heterotrimeric G protein family. In 2021, an article was reported that GPR156 modulates hair cell orientation in the cochlea. Also, it was proposed that GPR156 is related to congenital hearing loss. GPR156 in complex with any of the Gi/o heterotrimers regulates the hair cell orientation. In 2024, molecular structures of G-free and Go-bound GPR156 were characterized by using cryogenic electron microscopy.
Taste receptor type 2 member 10 is a protein that in humans is encoded by the TAS2R10 gene. The protein is responsible for bitter taste recognition in mammals. It serves as a defense mechanism to prevent consumption of toxic substances which often have a characteristic bitter taste.
Brian Kent Kobilka is an American physiologist and a recipient of the 2012 Nobel Prize in Chemistry with Robert Lefkowitz for discoveries that reveal the workings of G protein-coupled receptors. He is currently a professor in the department of Molecular and Cellular Physiology at Stanford University School of Medicine. He is also a co-founder of ConfometRx, a biotechnology company focusing on G protein-coupled receptors. He was named a member of the National Academy of Sciences in 2011.
David Jay Julius is an American physiologist and Nobel Prize laureate known for his work on molecular mechanisms of pain sensation and heat, including the characterization of the TRPV1 and TRPM8 receptors that detect capsaicin, menthol, and temperature. He is a professor at the University of California, San Francisco.
Nenad Ban is a biochemist born in Zagreb, Croatia who currently works at the ETH Zurich, Swiss Federal Institute of Technology, as a professor of Structural Molecular Biology. He is a pioneer in studying gene expression mechanisms and the participating protein synthesis machinery.
FAUC50 is a covalent agonist of the β2 adrenoceptor. It has been used as a template to form covalent agonists for other receptors.
beta-Fuoxymorphamine (β-fuoxymorphamine) is an opioid acting at μ-opioid receptors. It is used experimentally.
Kiyoshi Nagai was a Japanese structural biologist at the MRC Laboratory of Molecular Biology Cambridge, UK. He was known for his work on the mechanism of RNA splicing and structures of the spliceosome.
BU72 is an extremely potent opioid used in pharmacological research.
Ervin Fodor is a British virologist of Hungarian origin born in Czechoslovakia. He is Professor of Virology holding the position of reader in experimental pathology in the Sir William Dunn School of Pathology at the University of Oxford. He is also a professorial fellow at Exeter College, Oxford.
Stefan Raunser is a German scientist and structural biologist specializing in membrane proteins, the cytoskeleton, toxins, and sarcomere structural biochemistry. Since 2014, he has been a director at the Max Planck Institute of Molecular Physiology in Dortmund, Germany.